Protein Clinical Trials in Baltimore, Maryland
9 recruitingBaltimore, Maryland
Showing 1–9 of 9 trials
Recruiting
Phase 2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
Proteinuric Kidney Diseases
Boehringer Ingelheim132 enrolled147 locationsNCT07355296
Recruiting
Phase 2Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting
Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Chronic Kidney DiseaseProteinuria
Bayer219 enrolled164 locationsNCT05196035
Recruiting
Phase 3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled178 locationsNCT05457283
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Phase 1Phase 2
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.48 enrolled11 locationsNCT06430385
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Muscular DystrophyLimb Girdle Muscular DystrophyLGMD2I+6 more
AskBio Inc10 enrolled6 locationsNCT05230459
Recruiting
Phase 1Phase 2
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 enrolled1 locationNCT05950139
Recruiting
Not Applicable
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
Pediatric ALLMobilityMuscle Loss+1 more
Boston Children's Hospital72 enrolled2 locationsNCT05296096